Yavelov, I. S. (2020). Apixaban in non-valvular atrial fibrillation and treatment of venous thromboembolism: Universal safety advantage in different categories of patients. Remedium Group LLC.
Chicago Style (17th ed.) CitationYavelov, I. S. Apixaban in Non-valvular Atrial Fibrillation and Treatment of Venous Thromboembolism: Universal Safety Advantage in Different Categories of Patients. Remedium Group LLC, 2020.
MLA (8th ed.) CitationYavelov, I. S. Apixaban in Non-valvular Atrial Fibrillation and Treatment of Venous Thromboembolism: Universal Safety Advantage in Different Categories of Patients. Remedium Group LLC, 2020.
Warning: These citations may not always be 100% accurate.